Val­isure pres­sures FDA to re­call ac­ne treat­ments af­ter find­ing car­cino­gen

The drug test­ing com­pa­ny Val­isure is back with an­oth­er cit­i­zen pe­ti­tion re­lat­ed to safe­ty con­cerns, this time re­quest­ing the FDA re­call ac­ne treat­ments that con­tain ben­zoyl per­ox­ide, af­ter da­ta found that the car­cino­gen known as ben­zene can form at high lev­els in the prod­ucts.

Ac­cord­ing to Val­isure, prod­ucts with ben­zoyl per­ox­ide can form at over 800 times the con­di­tion­al­ly re­strict­ed FDA con­cen­tra­tion lim­it of 2 parts per mil­lion for ben­zene, as well as leak in­to the air out­side of the con­tain­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER